This website provides information about the business field of CO.DON GmbH, which has taken over the business operations from CO.DON AG.
Information on CO.DON Aktiengesellschaft can be found at www.codon-aktiengesellschaft.de.
The management of CO.DON GmbH is responsible for managing the company. It acts independently and is responsible for the company meeting the objectives laid down in its Rules of Procedure. To this end it takes the necessary entrepreneurial measures, i.e. decisions on staffing, finances and strategy.
A team of division managers assists the management with the development and implementation of the company strategy.
XING ZHAO, MD PhD., has been serving as the Managing Director of CO.DON GmbH since March 2023, and as the Chairman and Global CEO of ReLive Biotechnologies since 2021.
Dr. Zhao received his Ph.D. in Regenerative Medicine and Life Sciences from Utrecht University in the Netherlands and conducted postdoctoral research fellowship at Massachusetts General Hospital and Harvard Medical School in the United States, focusing on Tissue Engineering and Regenerative Medicine for cartilage repair and regeneration.
Dr. Zhao has more than 15 years of experiences in clinical practice, scientific discovery, innovative cell product development, and investments in the biotechnological field, particularly in regenerative medicine and cell therapy. In 2010, he became an Instructor of Orthopedic Surgery at Harvard Medical School. In 2015, he served as the Head of Research and the Chairman of the Scientific Advisory Board at Vericel Corporation (NASDAQ: VCEL), a leading regenerative medicine company in the United States. As a venture capitalist, he has invested in several biotech startups in the United States.
In 2021, he founded ReLive Biotechnology, a global regenerative medicine company group focused on Orthopedics, Plastic, and Reconstructive Surgery, operating in United States, Europe, and China, which acquired all assets from CO.DON AG in January 2023.
YING ZHOU, PhD has been appointed as the Managing Director since June 2023.
Dr. Ying Zhou is a renowned leader with a Ph.D. in Biochemistry from Boston University, School of Medicine. With over a decade of experience in the pharmaceutical and bio-pharmaceutical industries, including roles at AstraZeneca, Ambergen, and Alkermes, she has made significant contributions to Drug Discovery and Development.
Dr. Zhou co-founded ReLive Biotechnology, a global regenerative medicine company group focused on cell therapies, orthopedics, and plastic & reconstructive surgery. This innovative venture operates in the United States, Europe, and China, with a mission to transform the field of tissue engineering and regenerative medicine. Under her visionary leadership, ReLive Biotechnology acquired all assets from CO.DON AG in January 2023, positioning the company as a front-runner in the industry. Driven by her passion for scientific advancement and her commitment to improve patient care, Dr. Zhou continues to pave the way for groundbreaking treatments that harness the body's natural regenerative capabilities, which could significantly improve the patients' quality of life.